4.94
前日終値:
$5.19
開ける:
$5.09
24時間の取引高:
2.40M
Relative Volume:
1.79
時価総額:
$682.91M
収益:
$62.04M
当期純損益:
$-533.34M
株価収益率:
-1.2602
EPS:
-3.92
ネットキャッシュフロー:
$-473.07M
1週間 パフォーマンス:
+9.78%
1か月 パフォーマンス:
-17.39%
6か月 パフォーマンス:
-37.94%
1年 パフォーマンス:
-52.45%
Vir Biotechnology Inc Stock (VIR) Company Profile
名前
Vir Biotechnology Inc
セクター
電話
415-906-4324
住所
1800 OWENS STREET, SAN FRANCISCO, CA
VIR を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
VIR
Vir Biotechnology Inc
|
4.94 | 622.07M | 62.04M | -533.34M | -473.07M | -3.92 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
2023-09-08 | ダウングレード | BofA Securities | Buy → Neutral |
2023-03-06 | アップグレード | JP Morgan | Neutral → Overweight |
2023-02-21 | アップグレード | Goldman | Neutral → Buy |
2023-01-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
2022-09-14 | 開始されました | SVB Leerink | Outperform |
2022-09-09 | 開始されました | Morgan Stanley | Underweight |
2022-03-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
2021-12-21 | ダウングレード | Robert W. Baird | Neutral → Underperform |
2021-10-25 | アップグレード | JP Morgan | Underweight → Neutral |
2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
2021-06-04 | 再開されました | Robert W. Baird | Neutral |
2021-01-27 | ダウングレード | JP Morgan | Neutral → Underweight |
2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
2020-10-05 | 開始されました | BofA Securities | Buy |
2020-09-14 | アップグレード | Goldman | Neutral → Buy |
2020-09-11 | アップグレード | JP Morgan | Underweight → Neutral |
2020-08-20 | 開始されました | Needham | Buy |
2020-03-19 | ダウングレード | JP Morgan | Neutral → Underweight |
2020-03-13 | ダウングレード | Goldman | Buy → Neutral |
2020-02-27 | ダウングレード | Robert W. Baird | Neutral → Underperform |
2020-02-04 | ダウングレード | JP Morgan | Overweight → Neutral |
2019-11-14 | 開始されました | Robert W. Baird | Neutral |
2019-11-05 | 開始されました | Barclays | Overweight |
2019-11-05 | 開始されました | Cowen | Outperform |
2019-11-05 | 開始されました | Goldman | Buy |
2019-11-05 | 開始されました | JP Morgan | Overweight |
すべてを表示
Vir Biotechnology Inc (VIR) 最新ニュース
Vir Biotechnology Holds 2025 Annual Stockholder Meeting - TipRanks
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - BioSpace
Vir Biotechnology to Participate in the Goldman Sachs 46th Annua - GuruFocus
Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
Vir Biotechnology (VIR) Maintains 'Buy' Rating with $14 Price Ta - GuruFocus
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit - BioSpace
Vir Biotechnology stock target cut to $15 by H.C. Wainwright - Investing.com Australia
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit | VIR Stock News - GuruFocus
Vir Biotechnology’s SWOT analysis: HDV treatment potential lifts stock outlook - Investing.com Australia
Vir Biotechnology (VIR) Price Target Slashed Amid Clinical Trial Results | VIR Stock News - GuruFocus
How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com
How To Trade (VIR) - news.stocktradersdaily.com
Vir announces 24-week post-end of treatment data for Hep B therapy - MSN
Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus - MSN
Vir Biotechnology (VIR) Maintains 'Buy' Rating as Price Target A - GuruFocus
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference - BioSpace
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st
Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint - Yahoo Finance
Vir Biotechnology (VIR) Unveils Promising Hepatitis B Treatment Data | VIR Stock News - GuruFocus
Vir Biotechnology Announces Preliminary 24-Week Post-End of Trea - GuruFocus
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - BioSpace
Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Tr - GuruFocus
Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Treatment - GuruFocus
Vir Biotechnology Presents Promising Phase 2 Hepatitis B Data - TipRanks
Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Call Transcript - Insider Monkey
Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha
Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress - TipRanks
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | VIR Stock News - GuruFocus
Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha
Vir Biotechnology Reports Q1 2025 Financial Results - TipRanks
Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Advancements - GuruFocus
Vir Biotechnology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results - BioSpace
Vir Biotechnology Q1 2025 Earnings Call Transcript - MarketBeat
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq
Earnings call transcript: Vir Biotech Q1 2025 reports increased R&D expenses - Investing.com India
Vir Biotechnology (VIR) Falls Short on Q1 Revenue, Advances Clin - GuruFocus
Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 1c - StreetInsider
Vir Biotechnology Q1 2025 Earnings Preview - MSN
Vir Biotechnology Inc (VIR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):